SCHEMBL5899403

SCHEMBL5899403

O=C(C=C(O)c1nc[nH]n1)c1cc(C(=O)O)n(Cc2cccc(F)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.40
KDM4C Q9H3R0 2/20 0.39
NR4A2 P43354 2/20 0.36
P2RY14 Q15391 1/20 0.36
KDM5A P29375 2/20 0.36
KDM5B Q9UGL1 2/20 0.36
BRD4 O60885 1/20 0.35
GAA P10253 1/20 0.35
HCAR2 Q8TDS4 2/20 0.35
DBH P09172 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PTGER4 P35408 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672204 0.93 ALKBH1 (0.43) ALKBH1KDM4CNR4A2P2RY14KDM5A
SCHEMBL4671365 0.92 KDM4C (0.39) ALKBH1KDM4CNR4A2P2RY14BRD4
SCHEMBL4678137 0.89 OPRD1 (0.39) ALKBH1P2RY14BRD4GAAALDH1A1
SCHEMBL4676074 0.89 CA12 (0.39) ALKBH1KDM4CP2RY14KDM5AKDM5B
SCHEMBL4671850 0.89 KDM4C (0.40) ALKBH1KDM4CNR4A2BRD4GAA
SCHEMBL4676422 0.87 OPRD1 (0.41) ALKBH1P2RY14BRD4ALDH1A1LMNA
SCHEMBL4672392 0.86 OPRD1 (0.38) ALKBH1KDM4CP2RY14BRD4GAA
SCHEMBL4677554 0.86 GPR52 (0.37) ALKBH1KDM4CNR4A2P2RY14GAA
SCHEMBL4676597 0.85 KDM4C (0.37) ALKBH1KDM4CP2RY14KDM5AKDM5B
SCHEMBL4672821 0.84 USP2 (0.37) BRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALKBH1 333/4885KDM4C 785/4885NR4A2 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.